Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATNF 
180 Life Sciences Corp (ATNF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ATNF (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $80
1 Year Target Price $80
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -18.47% | Avg. Invested days 22 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price 80 |
Price to earnings Ratio - | 1Y Target Price 80 | ||
Volume (30-day avg) 1 | Beta 0.41 | 52 Weeks Range 0.66 - 12.74 | Updated Date 08/29/2025 |
52 Weeks Range 0.66 - 12.74 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.95 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.46% | Return on Equity (TTM) -371.02% |
Valuation
Trailing PE - | Forward PE 6.08 | Enterprise Value 474117853 | Price to Sales(TTM) - |
Enterprise Value 474117853 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.46 | Shares Outstanding 153032000 | Shares Floating 5040504 |
Shares Outstanding 153032000 | Shares Floating 5040504 | ||
Percent Insiders 9.99 | Percent Institutions 0.06 |
Upturn AI SWOT
180 Life Sciences Corp
Company Overview
History and Background
180 Life Sciences Corp. was formed through a merger in 2020, focusing on chronic inflammatory diseases. Its origins lie in research around anti-TNF therapy and other inflammatory pathways.
Core Business Areas
- Fibrosis & Anti-TNF: Developing therapeutics for fibrosis and related conditions, leveraging anti-TNF and other anti-inflammatory approaches.
- Early-Stage Fibrosis: Researching and developing treatments for early-stage fibrosis conditions.
- Inflammatory Diseases: Developing treatments for inflammatory diseases with unmet needs.
Leadership and Structure
Dr. James Woody is the CEO. The structure includes a board of directors and various scientific advisory boards.
Top Products and Market Share
Key Offerings
- Anti-TNF Therapy: Developing anti-TNF therapies for diseases like Dupuytrenu2019s contracture. Market share data unavailable due to development stage. Competitors include companies developing alternative therapies for Dupuytren's such as Xiaflex.
- SCAs: Developing therapies for Stages of Chronic Diseases. Market share data unavailable due to development stage. Competitors are other firms pursuing related treatments, but competition is limited given the early stage of the science.
Market Dynamics
Industry Overview
The biopharmaceutical industry is driven by innovation and demand for new treatments for chronic and inflammatory diseases. It's highly competitive and heavily regulated.
Positioning
180 Life Sciences is positioned as a clinical-stage biotech company focused on innovative therapies for unmet medical needs in fibrosis and inflammation. Its competitive advantage hinges on novel approaches.
Total Addressable Market (TAM)
The TAM for fibrosis and inflammatory disease treatments is estimated to be billions of dollars. 180 Life Sciences is targeting specific niches within this larger market, with a focus on early-stage intervention and innovative approaches.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Experienced leadership team
- Focus on unmet medical needs
- Strong scientific advisory board
Weaknesses
- Limited financial resources
- Clinical trial risks
- Limited revenue
- Reliance on funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory approvals
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- ABBV
- LLY
- AMGN
Competitive Landscape
180 Life Sciences faces intense competition from larger, well-established pharmaceutical companies. Success relies on demonstrating superior efficacy and safety profiles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its early stage as a clinical company.
Future Projections: Future growth projections are highly dependent on successful clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for their lead drug candidates and seeking partnerships.
Summary
180 Life Sciences Corp. is a high-risk, high-reward clinical-stage biotech company. The company needs to successfully execute its clinical trials and secure regulatory approvals. Its success depends heavily on the efficacy and safety of its therapies. Limited financial resources and strong competition pose significant challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 180 Life Sciences Corp
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Mr. Lloyd Blair Jordan L.L.B., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://180lifesciences.com |
Full time employees - | Website https://180lifesciences.com | ||
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.